Title:
TICAGRELOR-CONTAINING PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2016/169296
Kind Code:
A1
Abstract:
A drug inhibiting thrombosis, the active ingredient of the drug consisting of triflusal and ticagrelor having certain proportions, the mass ratio of the triflusal and the ticagrelor being 20 : 1 – 1 : 6. Experimental results show that the triflusal-ticagrelor composition has a much better effect of inhibiting thrombosis and combating platelet aggregation than an aspirin and clopidogrel composition (a control), and is better than triflusal alone and ticagrelor alone, and that the incidence of ulcers is lower than in a control group. Observations after a six month stability test show that the triflusal-ticagrelor composition has good stability, and is suitable for being made into an oral preparation.
Inventors:
CHEN XIULAN (CN)
Application Number:
PCT/CN2016/000141
Publication Date:
October 27, 2016
Filing Date:
March 18, 2016
Export Citation:
Assignee:
GUANGZHOU NUOWEI BIOTECHNOLOGY COMPANY LTD (CN)
International Classes:
A61K31/616; A61K31/519; A61P7/02; A61P9/10
Domestic Patent References:
| WO2014191321A1 | 2014-12-04 |
Foreign References:
| CN104434931A | 2015-03-25 | |||
| CN102406938A | 2012-04-11 | |||
| CN103764149A | 2014-04-30 |
Download PDF:
Previous Patent: CULTURE MEDIUM FOR IMMUNE CELLS AND ADDITIVE FOR CULTURE MEDIUM
Next Patent: WIND AND LIGHT COMBINED POWER GENERATION DEVICE
Next Patent: WIND AND LIGHT COMBINED POWER GENERATION DEVICE